Reviva Pharmaceuticals Holdings (RVPH) Stock Research

Over a week ago

Reviva Pharmaceuticals reports Q1 EPS (46c), consensus (29c)

RVPH

May 13, 5:01 PM

Reviva Pharmaceuticals cut to Hold at Maxim

RVPH

Apr 9, 7:53 AM

Maxim gets more bearish on Reviva Pharmaceuticals, downgrades shares

RVPH

Apr 8, 7:51 AM

Reviva Pharmaceuticals price target lowered by 50c at Roth Capital, here's why

RVPH

Mar 31, 9:34 PM

Reviva Pharmaceuticals price target raised by $14 at Alliance Global, here's why

RVPH

Mar 30, 12:41 PM

Reviva Pharmaceuticals prices $10M public offering at $1.50 per share

RVPH

Mar 19, 7:14 AM

Reviva Pharmaceuticals announces common stock, warrants offering

RVPH

Mar 18, 4:11 PM

Reviva Pharmaceuticals Holdings trading halted, news pending

RVPH

Mar 6, 7:50 PM

Reviva Pharmaceuticals announces 1-for-20 reverse stock split

RVPH

Mar 5, 8:50 AM

Reviva Pharmaceuticals just downgraded at D. Boral Capital, here's why

RVPH

Mar 5, 8:50 AM

Largest borrow rate increases among liquid names

Feb 3, 8:45 AM

Reviva announces publication on clinical vocal biomarker data from RECOVER trial

RVPH

Jan 8, 8:20 AM

Largest borrow rate increases among liquid names

Dec 30, 8:45 AM

Largest borrow rate increases among liquid names

Dec 24, 8:45 AM

Reviva Pharmaceuticals price target lowered by $1.50 at Roth Capital, here's why

RVPH

Dec 23, 3:34 PM

H.C. Wainwright still sees schizophrenia approval for Reviva in 2028

RVPH

Dec 23, 12:40 PM

Roth says Reviva may need additional $60M-$75M for schizophrenia study

RVPH

Dec 23, 9:21 AM

Reviva Pharmaceuticals announces regulatory update regarding brilaroxazine

RVPH

Dec 23, 8:16 AM

Reviva Pharmaceuticals discloses feedback from FDA on brilaroxazine

RVPH

Dec 23, 8:09 AM

Largest borrow rate increases among liquid names

Dec 17, 8:45 AM

Largest borrow rate increases among liquid names

Dec 15, 8:45 AM

Largest borrow rate increases among liquid names

Dec 10, 8:45 AM

Largest borrow rate increases among liquid names

Dec 8, 8:45 AM

Largest borrow rate increases among liquid names

Dec 2, 8:45 AM

Largest borrow rate increases among liquid names

Nov 25, 8:45 AM

Differentiated Mechanism of Action for Brilaroxazine: Reviva's lead candidate, brilaroxazine (RP1208), utilizes a unique serotonin-dopamine-glutamate modulation, which may offer a superior balance of efficacy and tolerability compared to current antipsychotic treatments.

Advanced Clinical Development Stage in Schizophrenia: Brilaroxazine is currently in Phase 3 clinical trials (RECOVER-1 and RECOVER-2) for schizophrenia, significantly de-risking the asset and accelerating its path towards potential market approval.

Addressing Significant Unmet Medical Needs in Schizophrenia: The company targets schizophrenia, a disorder with high unmet needs concerning the efficacy of current treatments, burdensome side effects (e.g., metabolic issues, EPS), and cognitive symptom management.

Clinical Trial Failure Risk: Brilaroxazine, RVPH's lead drug candidate, may not achieve its primary or secondary endpoints in ongoing or future clinical trials, or may show unexpected safety concerns, which would halt its development.

Regulatory Approval Uncertainty Risk: Even with positive clinical trial results, RVPH may not be able to obtain the necessary regulatory approvals from the FDA or other international agencies for Brilaroxazine, leading to significant delays or rejection.

Dependence on Lead Candidate Risk: RVPH's financial future and success are heavily reliant on the successful development and commercialization of Brilaroxazine. Failure of this single asset would severely impact the company.